viewKromek Group PLC

Kromek making big strides on all fronts and in a great place says CEO Basu

''The last year was a milestone for us'' says Arnab Basu, chief executive of medical and nuclear screening group Kromek PLC (LON:KMK).

''We won US$80mln of new contracts to make the total US$145mln over the past three years.''

''As these contracts are multi-year in nature we have visibility on 80% of revenues this year as well.''

Sales rose 23% in the year to April, underlying profits rose four-fold and losses halved and Basu expects further improvement in the current twelve months.

New standards are coming in for airport screening security while health authorities are realising diagnostics is a crucial way to improve the effectiveness of treatment.

Meanwhile, China and India are markets that are just opening up.

Quick facts: Kromek Group PLC

Price: 14.825 GBX

Market: AIM
Market Cap: £51.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kromek Group PLC named herein, including the promotion by the Company of Kromek Group PLC in any Content on the Site, the Company receives from...



Kromek Group CEO details DARPA extension and 'groundbreaking' pathogen...

Kromek Group PLC's (LON:KMK) Dr Arnab Basu speaks to Proactive London's Andrew Scott after reporting they've been awarded an extension to its contract with the Defense Advanced Research Projects Agency (DARPA) to detect and identify pathogens in an urban environment. Under the deal it will be...

on 27/5/20

2 min read